Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
132 results about "Thrombolytic Agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Any agent capable of dissolving an existing blood clot in order to reperfuse the blocked blood vessel.
Motion catheter
The present invention describes a catheter suitable for introduction into a tubular tissue for dissolving blockages in such tissue. The catheter is particularly useful for removing thrombi within blood vessels. In accordance with the preferred embodiments, a combination of vibrating motion and injection of a lysing agent is utilized to break up blockages in vessels. The vessels may be veins, arteries, ducts, intestines, or any lumen within the body that may become blocked from the material that flows through it. As a particular example, dissolution of vascular thrombi is facilitated by advancing a catheter through the occluded vessel, the catheter causing a vibrating, stirring action in and around the thrombus usually in combination with the dispensing of a thrombolytic agent such as urokinase into the thrombus. The catheter has an inflatable or expandable member near the distal tip which, when inflated or expanded, prevents the passage of dislodged thrombus around the catheter. The dislodged portions of thrombus are directed through a perfusion channel in the catheter, where they are removed by filtration means housed within the perfusion channel before the blood exits the tip of the catheter. Catheters that allow both frequency (1-1000 Hz) vibratory motion and delivery of such agents to a blockage and a method for using such catheters are disclosed.
Owner:TYCO HEALTHCARE GRP LP
Mechanically active infusion catheter
A device and method to dissolve or eliminate blood clots from a patient relies upon a non-rapid moving mechanism to physically dissolve clots without damaging endothelium of the arteries and veins of a patient. In one embodiment, in addition to mechanical agitation of a clot, a thrombolytic agent is administered simultaneously with such agitation. Preferably, intermittent agitation is utilized over a prolonged period of time to effectuate clot removal.
Owner:COOK MEDICAL TECH LLC
Low frequency vibration assisted blood perfusion emergency system
InactiveUS20050054958A1Improve localized drug effectivenessImprove vibrationElectrotherapySurgeryVascular obstructionFourth intercostal space
An emergency system for treatment of a patient (20) experiencing an acute vascular obstruction, employing a non-invasive vibrator (10), optimally in conjunction with drugs, for disrupting and lysing thromboses, relieving spasm (if associated), and thereby restoring blood perfusion. Vibrator (10) is operable in the sonic to infrasonic range, with a source output of up to 15 mm. For acute myocardial infarction cases, a pair of contacts (12), are advantageously placed to bridge the sternum at the fourth intercostal space. Vibration is initiated at 50 Hz (or any frequency, preferably within the 20-120 Hz range), and is ideally adjusted to a maximal amplitude (or force) deemed tolerable and safe to the patient (20), preferably with the administration of thrombolytic agents or other form of drug therapy. A synergistic effect is achieved between vibration and drugs to facilitate the disruption of thromboses, relieve spasm, and restore blood perfusion. In a variation, ultrasonic imaging may be used to direct vibration therapy.
Owner:PARALLEL BIOTECH LLP +1
Rotatable attachment mechanism for attaching a medical obstruction treatment device sub-assembly to a drive motor unit
InactiveUS6066152AEasy to replaceExcision instrumentsAbrasive surgical cuttersDrive shaftY connector
A miniaturized obstruction treatment device, e.g., a resilient brush, particularly adapted for medical use formed at the distal end of an elongated brush drive shaft having a hollow lumen formed therein for introduction over a guidewire. The brush drive shaft is enclosed in the lumen of a brush delivery catheter, and the brush is adapted to be garaged in a distal end section of the brush delivery catheter lumen. A Y-connector and a brush sub-assembly connector are attached to the proximal end of the brush delivery catheter and form a brush sub-assembly with the brush drive shaft and brush. The Y-connector allows infusion of thrombolytic agents into the brush delivery catheter lumen for emission at the distal end opening thereof adjacent the brush. In use, the brush sub-assembly connector connects the brush sub-assembly with a drive motor unit connector of a drive motor unit. The drive motor unit receives the proximal end of the drive shaft and rotates it to rotate the brush bristles. The brush and brush drive shaft distal section are automatically extended out of the catheter lumen distal end opening when the sub-assembly connector and the drive motor unit connector positively lock together. Simultaneously, a drive hub of the brush drive shaft locks into a drive chuck of a drive motor unit to enable rotation of the drive shaft, and the drive shaft proximal end is seated in a dynamic seal that inhibits infiltration of blood and thrombolytic agent into the drive motor housing.
Owner:TYCO HEALTHCARE GRP LP
Rotatable dynamic seal and guide for a medical obstruction treatment device sub-assembly coupled to a drive motor unit
A miniaturized obstruction treatment device, e.g., a brush, particularly adapted for medical use formed at the distal end of an elongated brush drive shaft having a hollow lumen formed therein for introduction over a guidewire. The brush drive shaft is enclosed in the lumen of an brush delivery catheter, and the brush bristles of the distal brush are adapted to be garaged in a distal end section of the brush delivery catheter lumen. A Y-connector and an brush sub-assembly connector are attached to the proximal end of the brush delivery catheter and form an brush sub-assembly with the brush drive shaft and brush. The Y-connector allows infusion of thrombolytic agents into the brush delivery catheter lumen for emission at the distal end opening thereof adjacent the brush. In use, the brush sub-assembly connector connects the brush sub-assembly with a drive motor unit connector of a drive motor unit. The drive motor unit receives the proximal end of the drive shaft and rotates it to rotate the brush bristles. The brush and brush drive shaft distal section are automatically extended out of the catheter lumen distal end opening when the sub-assembly connector and the drive motor unit connector positively lock together. Simultaneously, a drive hub of the brush drive shaft locks into a drive chuck of a drive motor unit to enable rotation of the drive shaft, and the proximal drive shaft end is seated in a dynamic seal that inhibits infiltration of blood and thrombolytic agent into the drive motor housing.
Owner:TYCO HEALTHCARE GRP LP
Thrombolysis device
A catheter suitable for dissolving blockages in tubular tissue provides a combination of low frequency (1–100 Hz) vibratory motion and injection of a lysing agent. The tubular tissue may be veins, arteries, ducts, intestines, or any other blocked body lumen. For vascular thrombi, the catheter may induce a vibrating, stirring action in and around the thrombus in combination with dispensing of a thrombolytic agent, such as urokinase, into the thrombus. An inflatable or expandable member may be provided near a distal tip of the catheter to prevent release of dislodged thrombus.
Owner:TYCO HEALTHCARE GRP LP
Function-enhanced thrombolytic AV fistula and method
A coiled stent graft, including a thrombolytic agent, is positionable within an AV fistula and optionally into one or both of the artery and the vein (6) to help reduce or eliminate blockages within the blood vessel at the junction between the AV fistula and the blood vessel.
Owner:LEMAITRE VASCULAR
Implantable device for delivering cardiac drug therapy
An implantable medical device in which an electrogram is recorded and analyzed in order to detect changes indicative of cardiac ischemia. Cardiac ischemia may be detected by recording an electrogram from a sensing channel of the device and comparing the recorded electrogram with a reference electrogram. If cardiac ischemia is detected, a cardiac drug such as a thrombolytic agent is delivered.
Owner:CARDIAC PACEMAKERS INC
Method for low temperature thrombolysis and low temperature thrombolytic agent with selective organ temperature control
InactiveUS6478811B1Small sizeIncreased activationDiagnosticsMedical devicesThrombusBiological activation
The invention provides a method for substantially reducing the size of a thrombus in a blood vessel in which blood is flowing. The method includes delivering a heat transfer element to a blood vessel in fluid communication with a thrombosed blood vessel. The temperature of the heat transfer element is adjusted such that the same is sufficient to remove heat from the flowing blood. Heat is transferred from a volume including the thrombus to the heat transfer element. In a separate embodiment, heat may be delivered to the volume including the thrombus from the heat transfer element. The resultant temperature of the volume may be sufficient to substantially reduce the size of a thrombus. For example, the resultant temperature of the volume may be sufficiently high to substantially enhance plasminogen activation near the thrombus. In a separate embodiment, a therapeutic drug may be delivered to the blood vessel to further reduce the size of a thrombus, the drug having an optimal temperature at the hypothermic or hyperthermic temperature of the blood.
Owner:ZOLL CIRCULATION
Method of treating stroke with thrombolytic agent
A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg / kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg / kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus. Also described are kits for carrying out this method.
Owner:GENENTECH INC
Thrombolysis device
InactiveUS6508782B1Easy to placeEasy to moveStentsElectrotherapyIntestinal structureWithin blood vessels
Owner:TYCO HEALTHCARE GRP LP
Method and apparatus for automatic location of blood flow with Doppler ultrasound
InactiveUS7425198B2Improve actionUltrasound therapyBlood flow measurement devicesDiagnostic modalitiesSonification
A method and apparatus for combining therapeutic pulsed or continuous-wave ultrasound with diagnostic pulsed ultrasound are described. In both a therapeutic mode and in a diagnostic mode, the ultrasound is administered from a single probe to a patient suffering from thrombosis. The ultrasound can have the same or different frequency ranges in the diagnostic and therapeutic modes. The pulsed or continuous-wave ultrasound in the therapeutic mode enhances a lysing effect of a thrombolytic agent. The pulsed ultrasound in the diagnostic mode allows monitoring of blood flow to locate a thrombus, to determine an optimal window to administer the therapeutic pulsed ultrasound, and to detect when recanalization has occurred. If an operator attends the device, a graphical display operates during the diagnostic mode to display an image representative of the blood flow.
Owner:SPENTECH
Method for low temperature thrombolysis and low temperature thrombolytic agent with selective organ temperature control
The invention provides a method for substantially reducing the size of a thrombus in a blood vessel in which blood is flowing. The method includes delivering a heat transfer element to a blood vessel in fluid communication with a thrombosed blood vessel. The temperature of the heat transfer element is adjusted such that the same is sufficient to remove heat from the flowing blood. Heat is transferred from a volume including the thrombus to the heat transfer element. In a separate embodiment, heat may be delivered to the volume including the thrombus from the heat transfer element. The resultant temperature of the volume may be sufficient to substantially reduce the size of a thrombus. For example, the resultant temperature of the volume may be sufficiently high to substantially enhance plasminogen activation near the thrombus. In a separate embodiment, a therapeutic drug may be delivered to the blood vessel to further reduce the size of a thrombus, the drug having an optimal temperature at the hypothermic or hyperthermic temperature of the blood.
Owner:ZOLL CIRCULATION
Method of treating stroke with thrombolytic agent
A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg / kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg / kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus. Also described are kits for carrying out this method.
Owner:GENENTECH INC
Method and apparatus for treatment of thrombosed hemodialysis access grafts
A method for the treatment of thrombosed hemodialysis access grafts or fistulas defining a shunt positioned between an arterial side and a venous side is achieved by inserting a balloon catheter within the shunt, wherein the balloon catheter includes a distal balloon and at least one infusion aperture located proximally of the distal balloon. Thereafter, the balloon catheter is advanced within an arterial anastomosis at an artery-shunt juncture and the distal balloon is inflated. A thrombolytic agent is then injected through the infusion apertures of the balloon catheter into the shunt to chemically destroy clot material within the shunt, wherein by applying the thrombolytic agent with the distal balloon inflated at the arterial anastomosis the possibility of the clot material moving into the artery is prevented and there is no need to worry about the migration of the clot into the arterial system and the resulting complications. Finally, the inflated distal balloon is pulled toward the venous side, eradicating the arterial plug. A balloon catheter for use in accordance with the present invention is also disclosed.
Owner:A V MEDICAL TECH +1
Method of treatment of thrombotic events
InactiveUS20030180282A1Salicyclic acid active ingredientsPeptide/protein ingredientsPlatelet inhibitorsThrombus
The present invention provides a method of treating a thrombotic or thromboembolic event in a patient by administering first a therapeutically effective amount of a thrombolytic agent and later a therapeutically effective amount of a platelet inhibitor, wherein the platelet inhibitor is administered after thrombolysis has occurred.
Owner:SEREBRUANY VICTOR +2
Medical device with therapeutic agents
A medical device is adapted for at least partial implantation into a body and includes first and second sections along the length of the device. A first therapeutic agent is associated with the first section and a second therapeutic agent is associated with the second section. The first therapeutic agent can be one or more antiproliferative, such as paclitaxel, a paclitaxel derivative, or a paclitaxel pro-drug, anti-coagulant, antithrombotic, thrombolytic, fibrinolytic, or combination thereof. The second therapeutic agent can be one or more antimicrobials, such as one or more antibiotics. Each of the first and second therapeutic agents can either be posited on one or more surfaces of the respective section, or impregnated within the section. The device can include a separator to space the first and second sections. A method of making a medical device and a method of establishing access to a vessel within a body are also provided.
Owner:COOK MEDICAL TECH LLC
Transcranial ultrasound thrombolysis system and method of treating a stroke
A method of transcranial ultrasound thrombolysis comprises the steps of providing a predetermined level of ultrasonic energy substantially throughout a primary treatment zone encompassing the M1 branch and M2 branches of the middle cerebral artery of an individual. A thrombolytic agent is also administered to the individual. A transcranial ultrasound thrombolysis system (10) is also provided that includes a transducer (20). The transducer is adapted to provide a predetermined level of ultrasonic energy substantially throughout a primary treatment zone encompassing at least a substantial portion of the M1 branch and the M2 branches of the middle cerebral artery in one hemisphere of a brain.
Owner:UNIVERSITY OF CINCINNATI
Implantable device for delivering cardiac drug therapy
An implantable medical device in which an electrogram is recorded and analyzed in order to detect changes indicative of cardiac ischemia. Cardiac ischemia may be detected by recording an electrogram from a sensing channel of the device and comparing the recorded electrogram with a reference electrogram. If cardiac ischemia is detected, a cardiac drug such as a thrombolytic agent is delivered.
Owner:CARDIAC PACEMAKERS INC
Compound with thrombus dissolving activity, as well as preparation and use thereof
The invention discloses a compound with thrombolytic activity as well as a preparation method and an application as the thrombolytic agent thereof. The 2-nitrogen or the 3-carboxyl of cyclized dopa is respectively coupled or latticed with H-Ala-Arg-Pro-Ala-Lys-OH, H-Pro-Ala-Lys-OH, H-Arg-Pro-Ala-Lys-OH, H-Gly-Arg-Pro-Ala-Lys-OH or H-Gln-Arg-Pro-Ala-Lys-OH to obtain the compound. The thrombolytic activity of the compound is evaluated by adopting the model of artery-vein bypass cannula thrombus in rats, and the experimental result shows that the compound has the excellent thrombolytic activity and can be clinically used as the thrombolytic agent. The therapeutic action of the compound to the cerebral infarction is further evaluated by adopting the model of cerebral thrombus in rats, and the experimental result shows that the compound has the excellent brain tissue protection action and can be clinically used as the thrombolytic agent.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Methods of thrombolytic organ treatment and repair
InactiveUS20020051779A1Improve survivabilityEffective therapyPeptide/protein ingredientsDead animal preservationStreptokinaseThrombus
The invention teaches methods and compositions for removing thrombi lodged in the microvasculature of an organ. To remove the thrombi, the organ may be perfused, flushed or washed with a suitable perfusion solution to which a sufficient amount of a thrombolytic agent, such as Streptokinase, has been added. The perfusing, flushing or washing process of the organ with the thrombolytic agent will promote thrombolysis on existing thrombi, prevent the formation of new thrombi in the organ, and / or open the vasculature of the organ thereby decreasing vascular resistance and increasing flow. The method of the invention may be practiced using an organ perfusion apparatus that would allow the viability of the organ to be sustained and / or restored upon perfusion with a thrombolytic agent.
Owner:ORGAN RECOVERY SYST
Composition And Methods Involving Thrombolytic Agents
InactiveUS20100143325A1Reduce riskReducing risk of mortalityPeptide/protein ingredientsCardiovascular disorderC1-inhibitorMedicine
Treatment or prevention methods are described wherein t-PA and C1-inhibtor are used together in order to minimize the hemorrhagic complications of tPA Preferably, C1-inhibitor is infused prior to treatment with t-PA, thereby allowing for a safer thrombolysis without the excessive and dangerous bleeding associated with the use of t-PA alone particularly in the treatment of ischemic stroke.
Owner:VASCULAR LAB
Intraventricular hemorrhage thrombolysis
InactiveUS20060078555A1Reduce mortalityIncreased mortalityBiocidePeptide/protein ingredientsSurgeryCerebral ventricle
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Clot removal system and method
A clot removal system includes first and second barriers that each have an expanded configuration forming an occlusion within a vessel and a collapsed configuration. At least one deployment device distally deploys the first barrier relative to a clot, and proximally deploys the second barrier relative to the clot. The at least one deployment device also delivers a thrombolytic agent into an isolated segment defined at least in part by the first and second barriers in the expanded configurations, and positions an impeller within the isolated segment. The impeller includes a substantially cylindrical hub having at least two impeller blades attached to rotate with the cylindrical hub. Each of the at least two impeller blades has a proximal end attached to the cylindrical hub and a distal end attached to the cylindrical hub. The impeller has a transport configuration in which the at least two impeller blades are moved toward the cylindrical hub and a deployed configuration in which the at least two impeller blades are moved away from the cylindrical hub.
Owner:COOK MEDICAL TECH LLC
Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and / or reducing infarct size is described which involves administering an effective amount of an ant-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
Owner:GENENTECH INC
Composition and method for enhancing fibrinolysis
The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministrating an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +2
Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
InactiveUS20090048216A1Inhibits thrombosis formationInhibits propagationBiocideSalicyclic acid active ingredientsAspirinOral medication
The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula:alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
Owner:ALEXION PHARMA INC
Neurovascular intervention device
The present invention generally relates to medical devices, and more particularly to an improved intravascular intervention device. In one embodiment, an intravascular intervention device includes a microcatheter configured for intravascular delivery, an imaging wire received within the microcatheter, and a treatment device received within the microcatheter, wherein the imaging wire and the treatment device may be simultaneously advanced. The treatment device is configured to perform intravascular intervention. For example, the treatment device may be configured to deliver a stent, an embolic coil and / or a thrombolytic agent. In this embodiment, the intravascular intervention device may image the area of interest while performing the intravascular intervention, thus allowing imaging to take place in real time.
Owner:SCI MED LIFE SYST
Thrombolysis catheter system with fixed length infusion zone
InactiveUS6884233B2Improve overall utilizationMaximize their optionUltrasonic/sonic/infrasonic diagnosticsStentsThrombusThrombolytic Agent
A thrombolysis catheter system having a fixed length infusion zone is disclosed. The invention contemplates apparatus, method and kit aspects. The apparatus, which has the capability to track a guidewire, uses a multilumen catheter to deliver radially thrombolytic agent to an infusion zone defined by one or more balloon means. In one aspect, with an occluder means, a primary lumen of the catheter is used both for catheter placement and delivery of fluid. The method discloses utilization of radiopaque indicia to place the catheter in proximity to the occlusion or diseased tissue to be treated. The kit includes a catheter of the invention in conjunction with a steerable guidewire and a tip occluder wire, either or both of the tip occluder wire and the guidewire having an enlargement on their distal tip which cooperates with a reduced diameter portion of the catheter lumen.
Owner:LAKE REGION MFG
Thrombolytic agents and methods of treatment for thrombosis
The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
Owner:BOARD OF RGT UNIV OF NEBRASKA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com